MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI, Aug. 5, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million, an increase of 7% year-over-year Diagnostics segment net revenues increased 36% year-over-year to a record $42.4 million Life Science segment delivered […]